enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 14.3% in July

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 800 shares, a growth of 14.3% from the June 30th total of 700 shares. Based on an average daily trading volume, of 6,200 shares, the days-to-cover ratio is presently 0.1 days.

enGene Stock Performance

Shares of ENGNW opened at $1.24 on Wednesday. enGene has a 52 week low of $0.39 and a 52 week high of $6.50. The stock’s 50-day moving average price is $1.70 and its 200-day moving average price is $2.86.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.